Advertisement

STAAR Surgical Company STAA

Set alert

Price alert · STAA

All alert types
24.54 USD -0.70 -2.77%

At close · Oct 30

24.54 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
24.55 × 2
Ask
24.56 × 2
24.32 Day range 25.42
16.10 52-week range 33.34
YTD
+6.28%
1 year
-7.50%
Open
25.21
Prev close
25.24
Mkt cap
1.23B
Vol
535.49K
Avg vol
898.48K
EPS
0.08
P/E
306.75
Div yield
0.00%
More statistics
Low
24.32
High
25.42
Forward P/E
22.08
Beta
1.18
Short ratio
3.76
Inst. own
111.59%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
22.39
200-d avg
23.59
1y target
27.67

5D chart

Chart tools
Interval
STAA five-day price chart22.123.023.824.725.5Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
1.23B
Enterprise value
1.12B
Trailing P/E
306.75
Forward P/E
22.08
PEG ratio
0.76
Price / sales
3.62
Price / book
3.37
EPS (TTM)
0.08
Beta
1.18
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
1.13%
Revenue (TTM)
339.59M
Revenue growth
111.00%
Free cash flow
15.35M
Total cash
181.49M
Total debt
35.94M
Return on equity
1.09%
Shares outstanding
50.14M
Short % of float
15.37%
50-day average
22.39
200-day average
23.59

Analyst view

Consensus: buy

Buy
Price target (mean) 27.67 +12.7% upside
Target (low)
19.00
Target (mean)
27.67
Target (high)
37.00
Ratings (0m) 11 4 buy · 6 hold · 1 sell
  • Strong buy0
  • Buy4
  • Hold6
  • Sell1
  • Strong sell0

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate 0.16857.

Earnings history

Financials — quick view

All financials
STAA Revenue — quarterly 93.53M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
STAA Net income — quarterly 8.06M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
STAA EPS — quarterly 0.16
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

STAA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Oct 3, 20260.05075———
Aug 12, 2026Jul 3, 20260.22140.16-0.06-27.73%
May 13, 2026Apr 3, 20260.054220.38+0.33+600.85%
Mar 3, 2026Jan 2, 20260.18-0.20-0.38-211.11%
Nov 5, 2025Sep 26, 20250.180.46+0.28+155.56%
Aug 6, 2025Jun 27, 2025-0.56-0.3395+0.22+39.38%

Upgrades / downgrades

STAA analyst upgrades and downgrades
DateFirmActionFromTo
Sep 29, 2026StifelupHoldBuy
Sep 22, 2026JefferiesmainBuyBuy
Aug 17, 2026StifelmainHoldHold
Aug 13, 2026UBSmainSellSell
Aug 13, 2026JefferiesmainBuyBuy
Aug 13, 2026WedbushmainOutperformOutperform

About STAAR Surgical Company

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Website
staar.com

News

Your note

Sign in to keep a note on STAA — it syncs with the Stock Master app.

Insider holders

STAA insider holders
InsiderRelationLatest transactionDateShares held
ANDREWS DEBORAH JChief Financial OfficerConversion of Exercise of derivative securityAug 13, 202638,910
BROADWOOD PARTNERS, L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseMar 12, 20260
BUTCHER ARTHUR CDirectorConversion of Exercise of derivative securityJun 17, 20269,549
FARRELL STEPHEN CChief Executive OfficerConversion of Exercise of derivative securityMar 4, 202535,156
FOUST WARRENChief Executive OfficerConversion of Exercise of derivative securityAug 13, 202695,816
JIANG WEIDirectorConversion of Exercise of derivative securityJun 17, 202677,127

Institution ownership

STAA institution ownership
Holder% heldSharesValueReported
Broadwood Capital, Inc.32.16%16,123,842395.68MJun 29, 2026
Blackrock Inc.13.42%6,731,154165.18MJun 29, 2026
Madison Avenue Partners, LP8.33%4,175,748102.47MJun 29, 2026
Yunqi Capital Ltd6.50%3,257,13079.93MJun 29, 2026
Point72 Asset Management, L.P.4.86%2,437,44659.81MJun 29, 2026
Goldman Sachs Group Inc4.29%2,150,80952.78MJun 29, 2026

Fund ownership

STAA fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF3.57%1,790,30943.93MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.89%949,46023.30MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.58%790,55819.40MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.37%684,66416.80MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.14%570,68814.00MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund0.78%392,9909.64MJun 29, 2026
Advertisement